Pharmaceutical News

RSS

54% of Americans are inconsistent in taking prescriptions, reveals survey

A new survey finds that 54 percent of Americans say they do not consistently take prescriptions as instructed even though 87 percent believe prescription medicines are important to their health – pointing to a growing public health problem.

12 Nov 2009

Nuvo Research announces new licensing agreement for Oxoferin

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a new licensing agreement for Oxoferin(TM), its topical wound healing agent, and additional details of the funding assistance to be provided by the Development Bank of Saxony for the development of WF10.

12 Nov 2009

Some benefits from prescription drug DTCA, but significant risks remain

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.

12 Nov 2009

FDA regulatory clearance for Kensey Nash's ECM product

Kensey Nash Corporation, a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration.

12 Nov 2009

CVS Caremark's medication adherence program for people with diabetes has positive impact

CVS Caremark said the company's comprehensive adherence program for people with diabetes positively impacts medication adherence for both new and continuing patients. A review of data tracking the program found that 75.6 percent of patients continuing on a diabetes therapy who participated in the adherence program maintained optimal adherence to their prescribed therapy vs. 61.2 percent in the control group.

12 Nov 2009

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. Those hard-to-treat diseases include malaria, tuberculosis, dengue fever, and other conditions. That's the topic of the cover story scheduled for the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

12 Nov 2009

CVS settles with NY over expired product sales; NC gets high-risk pool payment help

New York Attorney General Andrew Cuomo announced Tuesday that CVS, the drug story chain, has agreed to pay $875,000 to settle charges that it sold products years after their expiration dates, Reuters reports. The out-dated products, sold at 142 different stores, included "over-the-counter drugs, baby formula, eggs and milk," and in some cases items were sold more than two years after expiring (Stempel, 11/10).

11 Nov 2009

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients.

11 Nov 2009

Engineers develop technology to ensure "right first time" drug crystal formation in existing chemical reactors

Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation.

11 Nov 2009

Cholesterol-lowering drugs associated with reduced risk of gallstone disease

Use of the cholesterol-lowering drugs statins for more than a year is associated with a reduced risk of having gallstones requiring surgery, according to a study in the November 11 issue of JAMA.

11 Nov 2009

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

Duke University and Jubilant Organosys Limited, the largest integrated Custom Research and Manufacturing Services (CRAMS) and leading Drug Discovery and Development Services (DDDS) company in India, through its subsidiary, Jubilant Biosys Limited, today signed a Letter of Intent to develop a multi-faceted partnership that will expedite translation of discoveries by Duke scientists into clinical therapies.

11 Nov 2009

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

Researchers at the University of Illinois at Chicago have received a $4 million federal grant to develop new antibiotics to treat anthrax, tularemia and plague.

11 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

FDA Commissioner thanks America's doctors for their efforts during 2009 H1N1 influenza outbreak

Dr. Margaret Hamburg, Commissioner of Food and Drugs, today sent a letter to America's doctors, thanking them for their efforts during the 2009 H1N1 influenza outbreak and providing information on the safety of the 2009 H1N1 vaccines.

11 Nov 2009

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today that they have entered into agreements to expand and extend their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies.

11 Nov 2009

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.

11 Nov 2009

Lower socioeconomic status linked with inability to fight H1N1

People who did not earn a high school diploma could be more likely to get H1N1 and the vaccine might be less effective in them compared to those who earned a diploma, new research shows.

11 Nov 2009

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals, Inc. today announced nearly 20 presentations evaluating carfilzomib and ONX 0803 (SB 1518) in hematological cancers at the 51st American Society of Hematology (ASH) Annual Meeting December 5-8, 2009 in New Orleans, LA. Among the data presentations are four oral and seven poster presentations highlighting data from the carfilzomib development program in patients with relapsed and refractory multiple myeloma.

11 Nov 2009

Particle Sciences expands operations by acquiring new additional space

Particle Sciences Inc., a leading pharmaceutical CRO, has further expanded their capabilities by the acquisition of additional space bringing their total to approximately 21,000 sq ft.

11 Nov 2009

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding.

11 Nov 2009

Pharmaceutical News

54% of Americans are inconsistent in taking prescriptions, reveals survey

Nuvo Research announces new licensing agreement for Oxoferin

Some benefits from prescription drug DTCA, but significant risks remain

FDA regulatory clearance for Kensey Nash's ECM product

CVS Caremark's medication adherence program for people with diabetes has positive impact

Drug companies collaborate with nonprofit organizations to fight "neglected" diseases in the developing world

CVS settles with NY over expired product sales; NC gets high-risk pool payment help

FDA accepts Sol-Gel’s Investigational New Drug Application for DER45-EV Gel

Engineers develop technology to ensure "right first time" drug crystal formation in existing chemical reactors

Cholesterol-lowering drugs associated with reduced risk of gallstone disease

Duke University, Jubilant Organosys sign letter of intent for drug development partnership

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

Potential benefits of Labopharm's novel trazodone formulation published

FDA Commissioner thanks America's doctors for their efforts during 2009 H1N1 influenza outbreak

Sanofi-aventis, Regeneron sign agreement to expand development collaboration

Capecitabine in chemotherapy regimen reduces early breast cancer recurrence

Lower socioeconomic status linked with inability to fight H1N1

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Particle Sciences expands operations by acquiring new additional space

Allos Therapeutics awards NCCN a grant to evaluate pralatrexate

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News